InflaRx N.V. (IFRX) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Lyell Immunopharma (LYEL) over the past year, gaining 13.0% versus a loss of 51.6%. Over five years, IFRX leads with a -36.8% price change compared with -96.8% for LYEL. InflaRx N.V. is the larger company by market cap ($225.5 million vs $215.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | LYEL |
|---|---|---|
| Share price | $1.53 | $8.79 |
| Market cap | $225.47M | $215.40M |
| 1-day change | -1.92% | +2.69% |
| YTD return | +54.46% | -72.19% |
| 1-year return | +13.04% | -51.61% |
| 5-year return | -36.84% | -96.78% |
| EPS (TTM) | $-0.58 | $-12.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $45.00 |
| 52-week low | $0.798 | $8.21 |
| Distance from 52-week high | -48.12% | -80.47% |
| Analyst consensus | none | buy |
| Avg. price target upside | +400.65% | +330.94% |
| Average volume | 794.10K | 144.81K |
| Shares outstanding | 147.37M | 24.51M |
| Employees | 65 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed LYEL by 64.7 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
IFRX vs LYEL FAQ
Which is bigger, InflaRx N.V. or Lyell Immunopharma?
InflaRx N.V. (IFRX) is larger, with a market capitalization of $225.47M compared with $215.40M for Lyell Immunopharma (LYEL).
Which stock has performed better over the past year, IFRX or LYEL?
IFRX returned +13.04% over the past 12 months, compared with -51.61% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Lyell Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.